Bleomycin hydrochloride

Research use only, not for human use.

Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic.

Bleomycin hydrochloride is chosen as the best-studied micronucleus inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation. The IC50 value of Bleomycin hydrochloride for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin; IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively. Bleomycin hydrochloride (50, 100?μM; for 24, 48?h) induce pulmonary fibrosis in RLE-6TN cell (50?μM) and A549 cell (100?μM).(In Vitro):Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL.(In Vivo):Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment.

——

Animal Model:Male Fischer 344 rats, 8-10 week old, weighing 150-250?g Dosage:3.5-4 mg/kg Administration:Intra-tracheal Result:Body weights decreased by day 4 then increased by Day 7 through the end of the study.

——

Angiogenesis

PDGFR

N/A

——

——

67763-87-5

——

C50H71N16O21S2R.x(HCl)

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL

——

——

(-20℃)

With Ice Pack

≥ 2 years